Skip to main content
. 2023 Nov 27;8(6):102045. doi: 10.1016/j.esmoop.2023.102045

Figure 1.

Figure 1

Survival analyses. (A) Progression-free survival for all the series (n = 76); (B) progression-free survival according to line of therapy (ICI in first line versus subsequent lines); (C) progression-free survival according to response achieved by RECIST (complete/partial versus SD/PD); and (D) overall survival according to response achieved by RECIST (complete/partial versus SD/PD). CI, confidence interval; FL, first line; ICI, immune checkpoint inhibitor; mOS, median overall survival; mPFS, median progression-free survival; NR, not reached; PD, progressive disease; SD, stable disease; SL, subsequent line.